Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Denmark Patent 2,049,506

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Denmark Patent 2,487,161

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Denmark Patent 2,487,163

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Denmark Patent 2,487,166

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: Denmark Patent 3,150,586

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Denmark Patent 2,450,035

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Denmark Patent 2,450,035

EPIDUO FORTE is a drug marketed by Galderma Labs.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 21, 2026
Generic Entry Controlled by: Denmark Patent 2,046,332

RASUVO is a drug marketed by Medexus. There is one patent protecting this drug.

This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 28, 2026
Generic Entry Controlled by: Denmark Patent 1,912,999

OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.

This drug has sixty-four patent family members in forty-one countries. There has been litigation on patents covering OLYSIO

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: Denmark Patent 2,049,522

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: Denmark Patent 2,784,075

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: Denmark Patent 3,042,901

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Denmark Patent 1,931,316

CREON is a drug marketed by

This drug has ninety-three patent family members in thirty-one countries.

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: ticagrelor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 21, 2026
Generic Entry Controlled by: Denmark Patent 2,056,832

BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-seven suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.

Generic name: macitentan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2026
Generic Entry Controlled by: Denmark Patent 2,059,246

OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and one patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT

See drug price trends for OPSUMIT.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the macitentan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 01, 2026
Generic Entry Controlled by: Denmark Patent 1,919,874

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 01, 2026
Generic Entry Controlled by: Denmark Patent 1,919,874

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: pirfenidone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Denmark Patent 1,940,364

ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET

See drug price trends for ESBRIET.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.

Generic name: benzgalantamine gluconate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: Denmark Patent 1,940,817

ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.

Generic name: isavuconazonium sulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 25, 2026
Generic Entry Controlled by: Denmark Patent 2,068,842

CRESEMBA is a drug marketed by Astellas. There are three patents protecting this drug.

This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA

See drug price trends for CRESEMBA.

The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.

Generic name: abaloparatide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Denmark Patent 2,957,278

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

Generic name: fedratinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Denmark Patent 1,951,684

INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug.

This drug has one hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering INREBIC

See drug price trends for INREBIC.

The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the fedratinib hydrochloride profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: Denmark Patent 1,948,608

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: sacubitril; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Denmark Patent 2,340,828

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Denmark Patent 2,097,111

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

This drug has one hundred and sixteen patent family members in twenty-seven countries.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Denmark Patent 2,097,111

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

This drug has one hundred and sixteen patent family members in twenty-seven countries.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Denmark Patent 2,064,228

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: ambrisentan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Denmark Patent 2,101,777

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Denmark Patent 2,091,940

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Denmark Patent 3,176,159

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

Generic name: diazoxide choline
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Denmark Patent 1,968,601

VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.

This drug has seventy-nine patent family members in twenty-two countries.

The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the diazoxide choline profile page.

Generic name: ponatinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Denmark Patent 1,973,545

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.

Generic name: ponatinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Denmark Patent 2,495,016

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Denmark Patent 2,107,905

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Generic name: macimorelin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 19, 2027
Generic Entry Controlled by: Denmark Patent 1,984,744

MACRILEN is a drug marketed by Aeterna Zentaris. There is one patent protecting this drug.

This drug has eleven patent family members in ten countries.

See drug price trends for MACRILEN.

The generic ingredient in MACRILEN is macimorelin acetate. Two suppliers are listed for this generic product. Additional details are available on the macimorelin acetate profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Denmark Patent 2,079,445

PANCREAZE is a drug marketed by

This drug has eleven patent family members in ten countries.

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Denmark Patent 2,079,445

ZENPEP is a drug marketed by

This drug has eleven patent family members in ten countries.

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Denmark Patent 2,137,143

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

Generic name: axitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Denmark Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Denmark Patent 2,007,756

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.

This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Denmark Patent 2,674,428

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.

This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Denmark Patent 3,091,011

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.

This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Denmark Patent 2,135,199

QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Generic name: linagliptin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Denmark Patent 2,023,902

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Denmark Patent 2,152,237

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Denmark Patent 3,090,730

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Denmark Patent 4,218,732

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Denmark Patent 2,155,696

VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug.

This drug has one hundred and twenty-one patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Denmark Patent 2,164,473

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has one hundred and twenty-one patent family members in forty-two countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,164,467

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,500,014

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,164,467

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,500,014

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Denmark Patent 2,740,731

JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Denmark Patent 3,070,090

JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Denmark Patent 2,484,346

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Denmark Patent 2,719,378

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Denmark Patent 2,407,475

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: etripamil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Denmark Patent 2,170,050

CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug.

This drug has sixty-six patent family members in twenty-nine countries. There has been litigation on patents covering CARDAMYST

The generic ingredient in CARDAMYST is etripamil. One supplier is listed for this generic product. Additional details are available on the etripamil profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Denmark Patent 2,069,374

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Denmark Patent 2,069,374

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fourteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-seven patent family members in fifty-three countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Denmark Patent 2,069,374

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Denmark Patent 2,081,921

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,046,318

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,046,318

EPIDUO FORTE is a drug marketed by Galderma Labs.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,164,843

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,164,844

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,754,660

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Denmark Patent 2,016,940

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

This drug has thirteen patent family members in eleven countries.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Denmark Patent 2,016,940

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

This drug has twelve patent family members in eleven countries.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.

Generic name: lusutrombopag
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: Denmark Patent 2,184,279

MULPLETA is a drug marketed by Vancocin Italia. There are three patents protecting this drug.

This drug has forty-one patent family members in twenty countries.

See drug price trends for MULPLETA.

The generic ingredient in MULPLETA is lusutrombopag. Three suppliers are listed for this generic product. Additional details are available on the lusutrombopag profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Denmark Patent 2,173,891

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Denmark Patent 2,503,004

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Denmark Patent 2,503,005

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

Generic name: prasterone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Denmark Patent 2,185,157

INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug.

This drug has fifty-nine patent family members in thirty-two countries. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.

Generic name: gallium ga-68 gozetotide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Denmark Patent 2,187,965

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has fifty-five patent family members in sixteen countries.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the gallium ga-68 gozetotide profile page.